Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elexacaftor Triple Combination in CF Homozygous for F508del
NCT03525548Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Aug 2018
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 3 trial of elexacaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Started Aug 2018; status: completed.
02
Drugs
elexacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT03525548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03525548.